Esthesioneuroblastoma: An Update on the UCLA Experience, 2002–2013

Abstract

Objectives To profile the clinical presentation and treatment results of esthesioneuroblastomas at the University of California, Los Angeles (UCLA), from 2002 to 2013.

Design Retrospective review.

Setting Tertiary academic institution.

Participants Forty-one patients with esthesioneuroblastomas treated at UCLA.

Main Outcome Measures Overall survival (OS) and recurrence-free survival (RFS).

Results Thirty-six patients were included with a mean age of 50.1 years and a median duration of follow-up of 33 months. The 5-year RFS and OS were 54% and 82%, respectively. Modified Kadish stage was the only factor identified to affect OS. Multivariate analysis demonstrated that tumor grade was the only factor that had an independent impact on RFS. There was no statistical difference in survival among the surgical approaches chosen.

Conclusions The updated data on the UCLA experience reveals that all three surgical approaches chosen provide comparable survival, although longer follow-up will be needed to ascertain if these findings hold true. The endoscopic approach had a statistically significant decrease in length of hospital stay and a trend toward reduced blood loss, intensive care unit admission, and complications. The modified Kadish staging was the only factor identified to predict OS. Multivariate analysis revealed that tumor grade was an independent predictor of recurrence; therefore, its importance should be emphasized in future staging systems.

Keywords

esthesioneuroblastoma - olfactory neuroblastoma - sinonasal tumors - expanded endoscopic sinus surgery - anterior skull base surgery

Notes

This study was selected for oral presentation at the 24th Annual North American Skull Base Society meeting in San Diego, CA.

• References

• 1 Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 1976; 37 (3) 1571-1576
• 2 Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery 1993; 32 (5) 706-714 ; discussion 714–715
• 3 Biller HF, Lawson W, Sachdev VP, Som P. Esthesioneuroblastoma: surgical treatment without radiation. Laryngoscope 1990; 100 (11) 1199-1201
• 4 Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970–1990. Laryngoscope 1992; 102 (8) 843-849
• 5 Patel SG, Singh B, Stambuk HE , et al. Craniofacial surgery for esthesioneuroblastoma: report of an international collaborative study. J Neurol Surg B Skull Base 2012; 73 (3) 208-220
• 6 Song CM, Won TB, Lee CH, Kim DY, Rhee CS. Treatment modalities and outcomes of olfactory neuroblastoma. Laryngoscope 2012; 122 (11) 2389-2395
• 7 Nabili V, Kelly DF, Fatemi N, St John M, Calcaterra TC, Abemayor E. Transnasal, transfacial, anterior skull base resection of olfactory neuroblastoma. Am J Otolaryngol 2011; 32 (4) 279-285
• 8 Snyderman CH, Carrau RL, Kassam AB , et al. Endoscopic skull base surgery: principles of endonasal oncological surgery. J Surg Oncol 2008; 97 (8) 658-664
• 9 Gallia GL, Reh DD, Salmasi V, Blitz AM, Koch W, Ishii M. Endonasal endoscopic resection of esthesioneuroblastoma: the Johns Hopkins Hospital experience and review of the literature. Neurosurg Rev 2011; 34 (4) 465-475
• 10 Monteiro EM, Lopes MG, Santos ER , et al. Endoscopic treatment of esthesioneuroblastoma. Braz J Otorhinolaryngol 2011; 77 (2) 171-177
• 11 Jethanamest D, Morris LG, Sikora AG, Kutler DI. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg 2007; 133 (3) 276-280
• 12 Eloy JA, Vivero RJ, Hoang K , et al. Comparison of transnasal endoscopic and open craniofacial resection for malignant tumors of the anterior skull base. Laryngoscope 2009; 119 (5) 834-840
• 13 Wellman BJ, Traynelis VC, McCulloch TM, Funk GF, Menezes AH, Hoffman HT. Midline anterior craniofacial approach for malignancy: results of en bloc versus piecemeal resections. Skull Base Surg 1999; 9 (1) 41-46
• 14 Kane AJ, Sughrue ME, Rutkowski MJ , et al. Posttreatment prognosis of patients with esthesioneuroblastoma. J Neurosurg 2010; 113 (2) 340-351
• 15 Malouf GG, Casiraghi O, Deutsch E, Guigay J, Temam S, Bourhis J. Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome. Eur J Cancer 2013; 49 (6) 1324-1334
• 16 Ozsahin M, Gruber G, Olszyk O , et al. Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study. Int J Radiat Oncol Biol Phys 2010; 78 (4) 992-997
• 17 Kaur G, Kane AJ, Sughrue ME , et al. The prognostic implications of Hyam's subtype for patients with Kadish stage C esthesioneuroblastoma. J Clin Neurosci 2013; 20 (2) 281-286
• 18 Van Gompel JJ, Giannini C, Olsen KD , et al. Long-term outcome of esthesioneuroblastoma: Hyams grade predicts patient survival. J Neurol Surg B Skull Base 2012; 73 (5) 331-336